ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
0.00
0.00%
US Tech 100
21,213.60
1.06%
다우존스 지수
44,156.73
0.30%
Bitcoin
102,147.80
-1.44%
Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Kronos Bio Inc (KRON)

  7. Kronos Bio Inc (KRON) 뉴스

KRON

Kronos Bio (KRON)

Kronos Bio Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:KRON
일자시간출처헤드라인심볼기업
2024/11/2723:25AllPennyStocks.comCalifornia Biotech Stock Bid Up Prior To Opening Bell On Major AnnouncementNASDAQ:KRONKronos Bio Inc
2024/11/2721:30GlobeNewswire Inc.Kronos Bio Announces CEO Transition and Reduction in ForceNASDAQ:KRONKronos Bio Inc
2024/11/1514:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KRONKronos Bio Inc
2024/11/1506:02GlobeNewswire Inc.Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024NASDAQ:KRONKronos Bio Inc
2024/11/1406:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
2024/11/1406:05GlobeNewswire Inc.Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic AlternativesNASDAQ:KRONKronos Bio Inc
2024/11/0806:47Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KRONKronos Bio Inc
2024/11/0523:00GlobeNewswire Inc.Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple MyelomaNASDAQ:KRONKronos Bio Inc
2024/10/2321:55GlobeNewswire Inc.Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven TumorsNASDAQ:KRONKronos Bio Inc
2024/10/1607:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
2024/10/1607:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
2024/10/0921:55GlobeNewswire Inc.Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven TumorsNASDAQ:KRONKronos Bio Inc
2024/10/0721:55GlobeNewswire Inc.Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s DiseaseNASDAQ:KRONKronos Bio Inc
2024/09/2521:55GlobeNewswire Inc.Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory TherapyNASDAQ:KRONKronos Bio Inc
2024/09/2321:55GlobeNewswire Inc.Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian CancerNASDAQ:KRONKronos Bio Inc
2024/09/0321:55GlobeNewswire Inc.Kronos Bio Announces Participation in Medical and Investor Conferences in SeptemberNASDAQ:KRONKronos Bio Inc
2024/08/0905:15GlobeNewswire Inc.Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline UpdateNASDAQ:KRONKronos Bio Inc
2024/08/0905:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
2024/07/2405:15GlobeNewswire Inc.Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian CancerNASDAQ:KRONKronos Bio Inc
2024/06/0506:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
2024/06/0505:58Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
2024/05/2406:15GlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
2024/05/2305:30GlobeNewswire Inc.Kronos Bio to Participate in Three Upcoming Healthcare Conferences and EventsNASDAQ:KRONKronos Bio Inc
2024/05/2205:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRONKronos Bio Inc
2024/05/2121:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
2024/05/2121:15GlobeNewswire Inc.Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer NASDAQ:KRONKronos Bio Inc
2024/05/1005:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
2024/05/1005:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
2024/05/1005:05GlobeNewswire Inc.Kronos Bio Reports First-Quarter 2024 Financial ResultsNASDAQ:KRONKronos Bio Inc
2024/04/2505:01GlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
 검색 관련기사 보기:NASDAQ:KRON

최근 히스토리

CCOM
SILVER
SILVER
NASDAQ
MSFT
Microsoft
NYSE
AXP
American Express
NYSE
KO
Coca Cola
FX
USDEUR
US Dollar vs Euro
NYSE
BAC
Bank of America
AMEX
XLF
Financial Select Sector
NYSE
CVX
Chevron
NASDAQ
GOOGL
Alphabet
USOTC
RHHBY
Roche (QX)
FX
USDJPY
US Dollar vs Yen
CCOM
US500
US 500
NYSE
NKE
Nike
AMEX
XLV
Health Care Select Sector
COIN
DOGEUSD
Dogecoin
USOTC
ADDYY
Adidas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유